Tesamorelin is priced per 28-day pack of the brand, Egrifta WR. What you pay depends on insurance and the maker’s programs. The patient site prints no list price[2]. It routes patients through a benefits check instead[2].
That sets it apart from the price boards, which compare cash prices across many sellers. Tesamorelin has no board, because the brand is the only lawful product. Here the unit, the label and the payer set the cost.
28
Days of supply in one Egrifta WR pack
Source: Egrifta WR label
4
11.6 mg vials per pack
Source: Egrifta WR label
7
Days of daily doses from one mixed vial
Source: Egrifta WR label
What one pack holds
Egrifta WR comes as a package of two boxes[1]. The medication box holds four 11.6 mg single-patient-use vials[1]. The injection box holds the diluent and a 28-day supply of syringes, needles and alcohol swabs[1].
So supplies are inside the pack, where a cash peptide seller often bills them separately. The label dose is 1.28 mg once daily, and one mixed vial provides daily doses for 7 days[1].
There is a second formulation, Egrifta SV. The label states the two are not substitutable[1]. Price the one on the prescription.
Who it is approved for
Egrifta WR is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy[1]. The label adds that it is not indicated for weight loss, as it has a weight-neutral effect[1].
That matters for cost. Inside the indication, insurance and the maker’s programs apply. Outside it, a plan has less reason to pay.
How payment works
The maker’s support program starts with enrollment by the prescriber[2]. Its coordinators verify benefits and work with specialty pharmacies in the patient’s insurance network[2].
- Commercial insurance. Patients may be eligible for a co-pay assistance program[2].
- Government insurance. The program offers information and resources that may lower out-of-pocket costs[2].
- Patient assistance. Qualifying patients can receive the medication at no cost[2].
So the question to ask is not the list price. Ask what your plan’s specialty tier charges for a 28-day pack, and whether the co-pay program applies. The insurance guide explains why an approved brand is the case where coverage is possible at all.
What the trials found
A pooled analysis of two phase 3 trials randomized 806 adults with HIV and excess abdominal fat[3]. They received tesamorelin 2 mg or placebo daily for 26 weeks[3]. Egrifta WR is a different formulation, labeled at 1.28 mg[1].
Visceral fat fell by a treatment effect of 15.4% against placebo at week 26[3]. Abdominal fat under the skin did not change significantly[3]. Among patients kept on tesamorelin, the visceral fat reduction held to week 52[3].
Brand only: why no compounded price appears
FDA approved Egrifta in 2010 under a drug application. On March 23, 2020, that approval became a biologics license. FDA’s list of those changed approvals includes Egrifta and Egrifta SV, application 022505[4].
FDA’s notice to compounders from the same date says these products “will not be eligible for the exemptions for compounded drugs under sections 503A and 503B”[5]. Those two sections are how a pharmacy compounds lawfully. The approval history and the label’s limits are in is tesamorelin FDA approved.
Paying cash for a peptide instead? The fees beside the drug are in the peptide therapy cost guide.